Tony turns his attention to pivotal phase 3 trials and what mix of make or break biotechs you should have in your portfolio.

Several ASX companies are developing and providing technologies for reliable communications in remote areas, including Harvest Technology.

Graphene is gaining serious traction in Europe after major funding, while in Australia, Adisyn is positioning itself as a key ...

Neuren Pharmaceuticals and its US partner Acadia have been blitzing it with the Rett syndrome treatment Daybue.

Koonenberry Gold has lifted 30% on broad, high-grade results from the second diamond hole at Sunnyside prospect.

So, are we looking at a crash or a V-shaped recovery? Learn the six things every investor should probably know.

Riversgold (ASX:RGL) has returned another batch of wide gold intercepts from an ongoing perforation across its Northern Zone project.

ASX jumps on tariff relief, Wall Street ends strongly despite "Sell America" talk and Neuren and GGE take off.

EBR Systems (ASX:EBR) lands FDA approval for Wise CRT system, a world first solution proving pacing options for the left side of the heart.

Vertex Minerals (ASX:VTX) is tuning its processing plant to cater for a wider range of feedstock at its Reward Gold mine in New South Wales.

The US FDA has approved EBR System's leadless pacemaker WISE, the only heart device able to deliver left-ventricle ...

The spectacular cyber attack on super was aimed at larger funds – but SMSFs are equally exposed to new risks – here’s what to do.